Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Plans $4.3M Public Stock Offering

NEW YORK (GenomeWeb) – Interpace Diagnostics disclosed yesterday that it aims to raise roughly $4.3 million through the public offering of 630,000 shares of its common stock at a price of $6.81 per share.

Proceeds of the offering will be used for working capital, repayment of indebtedness, and general corporate purposes, the company said in a filing with the US Securities and Exchange Commission. Interpace said it will have approximately 2.8 million shares outstanding after the close of the offering.

During midday trading on the Nasdaq today, shares of Interpace were down 6.4 percent to $6.40.

Earlier this week, Interpace announced that it had signed a securities purchase deal with certain institutional investors that is expected to raise $3.7 million in net proceeds. Last month, the company entered into a stock purchase deal to raise $1.7 million, and effected a 1-for-10 reverse stock split in a bid to keep its shares listed on the Nasdaq.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.